Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter cohort of hengagliflozin + repagliptin + metformin vs dual combinations in type 2 diabetes mellitus
ChiCTR2400089642Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Integrative Medicine
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin, retagliptin and metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Guangdong Provincial Hospital of Integrative Medicine. Primary endpoint: glycated hemoglobin (HbA1c). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
henagliflozinretagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400089642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089642.